Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
IBIO vs COCP: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
IBIO Wins Head-to-Head Institutional Verdict (4–0 across 6 Pillars · 4–3 Matrix Metrics)
IBIO Overall Winner
6-Pillar Tally: IBIO 4 – 0 COCP (2 Tie)
Matrix Metrics: IBIO 4 – 3 COCP
As of Nov 16, 2026, iBio, Inc. (IBIO) is the stronger overall head-to-head candidate over Cocrystal Pharma, Inc. (COCP) in the Tradestie Institutional Equity Comparison Engine, winning 4–3 core matrix metrics and 4–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). IBIO carries a Unified Composite Score of 46.0/100 (HOLD) at $0.72 (N/M Forward P/E, -3025.6% operating margin), whereas COCP carries 47.1/100 (HOLD) at $1.00 (N/M Forward P/E, -3063.6% operating margin).
- Composite vs. Pillar Nuance: While COCP currently prints a higher short-term Unified Composite Score (47.1/100 HOLD vs. IBIO 46.0/100 HOLD), IBIO captures the overall institutional head-to-head verdict (4–3 matrix metrics and 4–0 across the 6 pillars) due to superior fundamental profitability (-3025.6% vs. -3063.6% operating margin) and revenue trajectory (+975.0% vs. +26.9% YoY).
- Technical & Structure Timing Caution: IBIO is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 37.7); meanwhile COCP trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 46.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About IBIO vs COCP
IBIO
Head-to-Head Winner
iBio, Inc. Common Stock
$0.72
-2.04% 1D
Market Cap
$53.7M
TTM Revenue
$1.1M
Forward P/E
N/M
Beta / 30D Vol
2.07β · 89% Vol
Unified Composite Score
46.0
HOLD
Tech 45.0
Fund 46.0
Flow 50.0
Mom 64.0
Weinstein Technical Phase
Markdown · Sell / avoid
COCP
Cocrystal Pharma, Inc. Common Stock
$1.00
+1.98% 1D
Market Cap
$19.6M
TTM Revenue
$330,000
Forward P/E
N/M
Beta / 30D Vol
1.04β · 54% Vol
Unified Composite Score
47.1
HOLD
Tech 51.0
Fund 48.0
Flow 50.0
Mom 54.0
Weinstein Technical Phase
Neutral · Hold
6-Pillar Scorecard Institutional Category Breakdown (IBIO 4 – 0 COCP)
1. Valuation Multiples
IBIO
Forward P/E
N/M
N/M
Trailing P/E
N/M
N/M
PEG Ratio
N/M
N/M
EV / Revenue
7.8x
49.7x
2. Growth & Scale
IBIO
Revenue Growth (YoY)
+975.0%
+26.9%
Earnings Growth (YoY)
+0.0%
+0.0%
TTM Revenue (USD)
$1.1M
$330,000
Market Cap
$53.7M
$19.6M
3. Profitability & Quality
IBIO
Gross Margin
100.0%
N/A
Operating Margin
-3025.6%
-3063.6%
Net Profit Margin
0.0%
0.0%
Return on Equity (ROE)
-51.8%
-311.7%
4. Balance Sheet & Cash Flow
IBIO
Cash Generation (TTM)
-$22M
-$7.6M
Cash Flow Margin
N/A
N/A
Net Cash / Leverage
$45M Net Cash
$3.3M Net Cash
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
Tie
Options Structure Phase
UNCLASSIFIED
UNCLASSIFIED
Current IV / %ile
N/A (N/A)
N/A (N/A)
Put/Call OI Skew
N/A
N/A
OBV Trend / Tech Phase
NEUTRAL · Markdown
NEUTRAL · Neutral
6. R&D & Supply-Chain Moat
Tie
OpEx & R&D Intensity
N/A
N/A
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
Cyclical / Execution-Driven Positioning
Supply-Chain Role
Biotechnology Operator
Biotechnology Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: IBIO (4) vs COCP (3)| Institutional Metric | IBIO | COCP | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $53.7M | $19.6M | IBIO | |
| Trailing P/E Ratio | N/M | N/M | Tie | |
| Forward P/E Ratio | N/M | N/M | Tie | |
| Revenue Growth (YoY) | +975.0% | +26.9% | IBIO | |
| Operating Margin (TTM) | -3025.6% | -3063.6% | IBIO | |
| Net Profit Margin | 0.0% | 0.0% | Tie | |
| Return on Equity (ROE) | -51.8% | -311.7% | IBIO | |
| 52-Week Range Position | 1% ($1–$4) | 19% ($1–$2) | COCP | |
| Beta / 30D Volatility | 2.07β · 89% Vol | 1.04β · 54% Vol | COCP | |
| Unified Institutional Score | 46.0 / 100 (HOLD) | 47.1 / 100 (HOLD) | COCP | |
| Trailing 12M Revenue (USD) | $1.1M | $330,000 | Scale | |
| Gross Profit Margin (TTM) | 100.0% | N/A | Quality | |
| PEG Ratio & EV / Revenue | N/M PEG · 7.8x EV/Rev | N/M PEG · 49.7x EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | -$22M ($45M Net Cash) | -$7.6M ($3.3M Net Cash) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
COCP +4.45 pp
3M Horizon
COCP +43.12 pp
6M Horizon
COCP +34.22 pp
1Y Horizon
COCP +34.71 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | IBIO Revenue | COCP Revenue | IBIO Op. Margin | COCP Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2018 | $0M | N/A | -3204.3% | N/A | IBIO |
| FY2019 | $0M | $10M | -782.4% | -737.4% | COCP |
| FY2020 | $0M | $0M | -854.9% | -476.0% | COCP |
| FY2021 | $0M | N/A | -1312.1% | N/A | IBIO |
| FY2022 | $0M | N/A | -1576.3% | N/A | IBIO |
| FY2024 | $0M | N/A | -7392.9% | N/A | IBIO |
| FY2025 | $0M | N/A | -4650.5% | N/A | IBIO |
| FY2026 | $0M | N/A | -35141.0% | N/A | IBIO |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
IBIO
UNCLASSIFIED
Current IV
N/A
IV Percentile
N/A
Put/Call OI Skew
N/A
IV Regime
Unclassified
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
NEUTRAL
Exact IBIO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
COCP
UNCLASSIFIED
Current IV
N/A
IV Percentile
N/A
Put/Call OI Skew
N/A
IV Regime
Unclassified
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
NEUTRAL
Exact COCP Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
IBIO Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
COCP Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
Investor FAQ IBIO vs COCP Key Questions & Quantitative Answers
As of Nov 16, 2026, iBio, Inc. (IBIO) is the stronger overall head-to-head candidate over Cocrystal Pharma, Inc. (COCP) in the Tradestie Institutional Equity Comparison Engine, winning 4–3 core matrix metrics and 4–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). IBIO carries a Unified Composite Score of 46.0/100 (HOLD) at $0.72 (N/M Forward P/E, -3025.6% operating margin), whereas COCP carries 47.1/100 (HOLD) at $1.00 (N/M Forward P/E, -3063.6% operating margin). Composite vs. Pillar Nuance: While COCP currently prints a higher short-term Unified Composite Score (47.1/100 HOLD vs. IBIO 46.0/100 HOLD), IBIO captures the overall institutional head-to-head verdict (4–3 matrix metrics and 4–0 across the 6 pillars) due to superior fundamental profitability (-3025.6% vs. -3063.6% operating margin) and revenue trajectory (+975.0% vs. +26.9% YoY). Technical & Structure Timing Caution: IBIO is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 37.7); meanwhile COCP trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 46.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
IBIO leads the Growth & Scale pillar: IBIO posts +975.0% YoY revenue growth and +0.0% YoY earnings growth on $1.1M TTM revenue (100.0% gross margin, -3025.6% operating margin), compared with COCP at +26.9% YoY revenue growth and +0.0% YoY earnings growth on $330,000 TTM revenue (N/A gross margin, -3063.6% operating margin). Across the 8-period historical trajectory (FY2018 to FY2026), IBIO cumulative revenue shifted N/A while COCP shifted N/A. In operating R&D and SG&A reinvestment, IBIO deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for COCP.
IBIO screens cheaper on headline valuation multiples. IBIO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 7.8x EV/Revenue (unreported FCF margin), whereas COCP trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 49.7x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against IBIO (-51.8% ROE) versus COCP (-311.7% ROE) capital efficiency.
In options market volatility and institutional positioning, IBIO carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (2.07β · 89% Vol realized risk). By comparison, COCP carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.04β · 54% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
COCP vs IBIO · Reverse Pair
COCP vs PRPO
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem
LLY vs NVO
· GLP-1 Biopharma
AVGO vs MRVL
· Custom ASIC & Networking
VRT vs ETN
· AI Power & Thermal